Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Capital Expenditures (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Capital Expenditures for 7 consecutive years, with -$15000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to -$15000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $218000.0 for FY2024, N/A changed from the prior year.
  • Capital Expenditures for Q4 2025 was -$15000.0 at Soleno Therapeutics, down from $1000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $9000.0 in Q2 2025, with the low at -$15000.0 in Q4 2025.